NYSE · RFL.WS
Rafael Holdings, Inc.. to Purchase of
$0.01 -$0.02 (-52.67%) 1DKey Metrics
$728.86K
Market cap
—
P/E · TTM
$980.00K
Revenue · TTM
−$32.55M
Net income
EPS · TTM
$-0.63
Dividend yield
—
Free cash flow
−$31.99M
Beta · 1Y
—
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap—
Enterprise value−$8.62M
Shares outstanding—
52-wk range$0.01 – $0.20
Avg volume · 20D12.1K
Net cash
$9.35M
Book value / share$1.47
IndustryPharmaceutical Preparations
ExchangeNYSE
About Rafael Holdings, Inc.. to Purchase of
IPO dateApr 1, 2025
Employees23
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S0.74
P/FCF—
EV/EBITDA—
EV/Sales-8.79
Graham №—
Profitability
Gross
—
Operating
-3,182.2%
Net
-3,321.7%
FCF
-3,264.7%
ROE / ROIC
-43.2% · -46.5%
Financial Health
Current ratio3.16
Quick ratio3.14
Debt / equity0.29
Debt / EBITDA
—
Net cash
$9.35M
Working capital$23.84M
Cash Flow · TTM
Operating CF
−$31.99M
Capex
−$4.00K
Free cash flow
−$31.99M
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
1 / 9
Weak fundamentals · 1 of 9 signals passing
Altman Z-Score
-4.6
Distress zone (< 1.81) · elevated risk
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-04-30 · computed by TickerWolf from SEC filings